BD-1063

BD-1063 (5.6-56.2 mg/kg; subcutaneous administration) produces dose-dependent anti-allodynic and anti-hyperalgesic effects in a rat CCI neuropathic pain model, with an ED₅₀ value of 28.8 mg/kg for anti-hyperalgesia and 18.2 mg/kg for anti-allodynia; it also exerts a synergistic effect with Quercetin hydrate (HY-18085A)^[1].
BD-1063 (4-16 mg/kg; subcutaneous injection) completely reverses carrageenan (HY-125474)-induced inflammatory mechanical hyperalgesia and thermal hyperalgesia in wild-type CD-1 mice via a σ₁ receptor-mediated mechanism, with ED₅₀ values of 4 mg/kg and 6 mg/kg, respectively, and does not affect nociceptive pain in non-inflamed mice^[3].
BD-1063 (25-75 μg/paw; intraplantar injection) fully reverses carrageenan (HY-125474)-induced mechanical hyperalgesia and thermal hyperalgesia in wild-type CD-1 mice via a σ₁ receptor-mediated mechanism, without producing systemic effects^[3].
BD-1063 (4.4-11 mg/kg; subcutaneous injection) reduces ethanol self-administration behavior in male Wistar rats with ethanol dependence during acute withdrawal in a dose-dependent manner, and the 11 mg/kg dose produces significant inhibitory effects in all test subjects^[4].
BD-1063 (3-11 mg/kg; subcutaneous injection) reduces ethanol self-administration in genetically selected male Sardinian alcohol-preferring rats in a dose-dependent manner, with significant inhibitory effects observed at doses of 4.4 mg/kg and higher^[4].